ROCHE HOLDINGS AG(RHHVF.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
ROCHE HOLDINGS AG
RHHVF.US
4.853 T
RHHVF.USMarket value -Rank by Market Cap -/-

Financial Score

22/01/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking3/186
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE32.73%A
    • Profit Margin14.85%A
    • Gross Margin75.67%A
  • Growth ScoreB
    • Revenue YoY8.89%B
    • Net Profit YoY-7.74%C
    • Total Assets YoY11.12%B
    • Net Assets YoY12.89%B
  • Cash ScoreB
    • Cash Flow Margin673.33%C
    • OCF YoY8.89%B
  • Operating ScoreB
    • Turnover0.67B
  • Debt ScoreD
    • Gearing Ratio65.13%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Ascendis Pharma rises amid takeover speculation

    Ascendis Pharma rises amid takeover speculation

    businessinsider·
    US
    ASND
    +4.06%
    businessinsider·
    US
    ASND
    +4.06%

    Swiss stocks - Factors to watch on January 21

    Swiss stocks may be influenced by several factors on January 21. ALCON AG has completed a $750 million share repurchase program. UBS is considering external CEO candidates, according to CEO Ermotti. ROCHE's Genentech plans to increase its investment in a North Carolina biomanufacturing facility to $2 billion. BARRY CALLEBAUT AG appointed Hein Schumacher as its new CEO, effective January 26, with Q1 results expected at 0700 GMT. Jefferies has cut the target price for PARTNERS GROUP HOLDING AG to CHF 1,130. Swiss December money supply M3 and SNB US Dollar auction are also due.

    Reuters·
    US
    SBIO
    +2.17%
    US
    XBI
    +2.62%
    US
    ARKG
    +5.74%
    Reuters·
    US
    SBIO
    +2.17%
    US
    XBI
    +2.62%
    US
    ARKG
    +5.74%

    Genentech To Create Additional 100 Jobs With Further Investment In North Carolina Facility

    Genentech, a subsidiary of Roche Holding AG, announced a $2 billion expansion of its manufacturing facility in Holly Springs, North Carolina, which will create an additional 100 jobs. The project will support over 500 high-wage manufacturing jobs and 1,500 construction jobs, with operations expected to begin by 2029. This investment underscores Genentech's commitment to the U.S. market and aims to enhance production capacity. Roche's stock is currently trading at $54.56, reflecting a 0.59% increase.

    rttnews·
    US
    XBI
    +2.62%
    US
    ARKG
    +5.74%
    US
    SBIO
    +2.17%
    rttnews·
    US
    XBI
    +2.62%
    US
    ARKG
    +5.74%
    US
    SBIO
    +2.17%

    Genentech More than Doubles Investment in Holly Springs, North Carolina Manufacturing Facility | RHHBY Stock News

    Genentech is increasing its investment in a biomanufacturing facility in Holly Springs, North Carolina, to approximately $2 billion, more than doubling its initial commitment. This expansion will enhance production capacity and create over 2,000 jobs, including 500 high-wage manufacturing positions. The facility, set to be operational by 2029, will focus on next-generation treatments for metabolic conditions. This investment aligns with Roche and Genentech's broader $50 billion commitment to U.S. manufacturing and reflects confidence in the local workforce and innovation potential.

    StockTitan·
    US
    IHE
    +0.63%
    US
    PBE
    +0.94%
    US
    IBB
    +1.55%
    StockTitan·
    US
    IHE
    +0.63%
    US
    PBE
    +0.94%
    US
    IBB
    +1.55%

    MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum | MAIA Stock News

    MAIA Biotechnology has advanced its ateganosine cancer treatment program, highlighting significant achievements in 2025 and outlining key milestones for 2026. The FDA granted Fast Track designation for ateganosine in treating non-small cell lung cancer (NSCLC), supporting concurrent Phase 2 and Phase 3 trials. The company aims for early commercial approval within 18-24 months, backed by strong clinical data and partnerships. Key 2026 targets include interim efficacy measures from Phase 3 studies and regulatory discussions with the FDA.

    StockTitan·
    US
    BIB
    +3.93%
    US
    FBT
    +1.64%
    US
    LABD
    -7.96%
    StockTitan·
    US
    BIB
    +3.93%
    US
    FBT
    +1.64%
    US
    LABD
    -7.96%
    Posts
    View More

    $Recursion Pharmaceuticals(RXRX.US) Recursion Pharmaceuticals Inc.（RXRX）Weekly Report (2025.11.22-11.29) The extent of your achievements can largely be seen from how much pain you can endure...

    © 2026 Longbridge｜Disclaimer